Edwards Lifesciences Reports Q3 2024 Financial Results

Details

TAVR sales increased by 6% (7% on a constant currency basis), and TMTT sales surged by 73%. The company reported Q3 EPS of $5.13 (adjusted EPS of $0.67), slightly ahead of guidance. The strong performance was driven by robust contributions from both TAVR and TMTT product groups. A press release detailing the financial results is furnished as Exhibit 99.1.

Items reported

Exhibits (1)

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.